GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NLS Pharmaceutics Ltd (NAS:NLSP) » Definitions » Current Ratio

NLS Pharmaceutics (NLS Pharmaceutics) Current Ratio : 0.23 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is NLS Pharmaceutics Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. NLS Pharmaceutics's current ratio for the quarter that ended in Dec. 2023 was 0.23.

NLS Pharmaceutics has a current ratio of 0.23. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If NLS Pharmaceutics has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for NLS Pharmaceutics's Current Ratio or its related term are showing as below:

NLSP' s Current Ratio Range Over the Past 10 Years
Min: 0.03   Med: 0.58   Max: 6.91
Current: 0.58

During the past 7 years, NLS Pharmaceutics's highest Current Ratio was 6.91. The lowest was 0.03. And the median was 0.58.

NLSP's Current Ratio is ranked worse than
88.8% of 1553 companies
in the Biotechnology industry
Industry Median: 3.79 vs NLSP: 0.58

NLS Pharmaceutics Current Ratio Historical Data

The historical data trend for NLS Pharmaceutics's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NLS Pharmaceutics Current Ratio Chart

NLS Pharmaceutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial 0.09 0.03 2.38 2.75 0.23

NLS Pharmaceutics Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.38 0.59 2.75 0.58 0.23

Competitive Comparison of NLS Pharmaceutics's Current Ratio

For the Biotechnology subindustry, NLS Pharmaceutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NLS Pharmaceutics's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NLS Pharmaceutics's Current Ratio distribution charts can be found below:

* The bar in red indicates where NLS Pharmaceutics's Current Ratio falls into.



NLS Pharmaceutics Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

NLS Pharmaceutics's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=1.823/7.92
=0.23

NLS Pharmaceutics's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=1.823/7.92
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NLS Pharmaceutics  (NAS:NLSP) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


NLS Pharmaceutics Current Ratio Related Terms

Thank you for viewing the detailed overview of NLS Pharmaceutics's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NLS Pharmaceutics (NLS Pharmaceutics) Business Description

Traded in Other Exchanges
N/A
Address
The Circle 6, Zurich, CHE, 8058
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.